3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
4
Terminated
3
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Breast Neoplasms
43
Neoplasm Metastasis
5
Neoplasms
4
Ovarian Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Carcinoma, Non-Small-Cell Lung
3
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Cancer Metastatic
2
Advanced Breast Cancer
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Lymphoma, Non-Hodgkin
1
Hyperglycemia
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
Female Breast Carcinoma
1
Exanthema
1
Carcinosarcoma
1
Carcinoma, Lobular
1
Breast Neoplasms, Male
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Adenocarcinoma Of Esophagus
1
Interventions
Fulvestrant
3
Alpelisib
3
duvelisib
2
Cetuximab
2
volagidemab
1
talazoparib
1
ruxolitinib
1
parsaclisib
1
olaparib
1
obinutuzumab
1
lorlatinib
1
encorafenib
1
dapagliflozin
1
cobimetinib
1
chiauranib
1
binimetinib
1
avelumab
1
Vemurafenib
1
SF 1126
1
Rituximab
1
NVP-BKM120
1
Drug Therapy
1
CYH33
1
Aspirin
1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Terminated
×
Hereditary Sensory and Autonomic Neuropathies
×
Fulvestrant
×
Clear all
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts
NCT03386162
2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2
Terminated
31 enrolled
NCT01633060
2019-01-30
BELLE-3
Novartis
Phase 3
Terminated
432 enrolled
20 charts